Led · Equity · Jun 2026

Alloy operates a telehealth platform that links women with physicians trained in menopause care, offering clinician community support and annual in-person training for its providers. The company emphasizes capital-efficient growth, claiming near-zero physician attrition and zero recruiting costs because clinicians join organically. Alloy reached profitability around its Series A in November 2024 and has since reinvested earnings into growth rather than hoarding cash. Its leadership, including co‑founders and co‑CEOs Anne Fulenwider and Monica Molenaar, positions the company as deliberately disciplined compared with better‑funded peers. The broader market context cited in reporting notes roughly 1.3 million U.S. women enter menopause each year and a global menopause market valued at about $17.8 billion in 2024. Alloy is pursuing a retention- and unit-economics-driven expansion rather than rapid, capital-intensive scaling.

Participated · Series A · Nov 2025

Nest Health delivers integrated medical, behavioral, and social care to entire households, replacing the fragmented experience of juggling pediatric, adult, and mental-health providers. Families receive age- and stage-aligned in-home visits augmented by virtual consultations, 24/7 clinical support, and coordinated referrals to specialists. The company’s offering spans primary care, mental-health and substance-use treatment, and social-needs assistance such as housing or utilities support. Its AI tools automate workflows before, during, and after caregiver interactions to boost care-team efficiency. Founded by Dr. Rebekah Gee, Nest Health currently operates in Louisiana and Arizona and targets Medicaid populations. The fresh $22.5 million Series A financing strengthens its balance sheet and will fund expansion of its AI-driven clinical products and geographic footprint through new and existing payer partnerships.

Led · Seed · Oct 2025

Allswell is an early-stage digital health company that delivers virtual one-on-one and group therapy tailored to LGBTQ+ adults. Its clinicians, primarily licensed social workers, use affirmative cognitive behavioral therapy as well as cognitive processing therapy and eye-movement desensitization and reprocessing to address trauma and minority stress. The platform is in-network with Maryland Medicaid, UnitedHealthcare, CareFirst and Cigna, and it also accepts cash payment, enabling access for a predominantly Medicaid population. According to the company, 83% of patients experience reduced depression symptoms within four to eight weeks. Founded in 2024, Allswell currently operates only in Maryland but plans to expand across additional states and reach the full Washington, D.C.–Maryland–Virginia region by early 2026. Proceeds from its recent pre-seed raise will support growth of its therapist network and the development of AI-enabled digital tools such as journaling features and skills-practice worksheets.

Participated · Series A · Jan 2025

Granata Bio is a Boston, MA–based biopharmaceutical company advancing fertility therapeutics and women’s health. Led by CEO Evan Sussman, the company’s pipeline includes a range of fertility therapies developed through collaborations spanning multiple drug classes. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing therapeutics to preserve ovarian function and extend female health span. The company received an investment from Gedeon Richter; the amount of the deal was not disclosed. Granata Bio said it will use the funds to expand operations and its R&D efforts. No operating metrics or past financing details were provided in the article. Granata Bio is a US-based biopharma company focused on women's health and reinvigorating the $3.6B global infertility medication market. Its pipeline includes collaborations spanning multiple IVF product classes. The company aims to identify and develop new therapeutic solutions to improve access for fertility patients. With the new funding, Granata plans to progress its existing pipeline and explore additional innovative assets in reproductive health. Granata emphasizes strengthening its leadership position within the reproductive health space and growing solutions for patients. Granata was founded in 2018. Granata Bio is a biopharma company focused on women’s health and the infertility medication market, led by CEO Evan Sussman. The company has assembled a portfolio of four medications that range from commercialized products to early-stage developments. Granata intends to use the new funding to progress its existing pipeline, evaluate new targets, and expand its team. The company raised $14M in a Series A to support those plans. Granata is based in Boston, MA. No revenue or user metrics were disclosed in the article.

Participated · Seed · May 2024

Testmate Health is a Lausanne, Switzerland-based company developing over-the-counter (OTC) at-home self-tests for sexually transmitted infections. It is led by CEO Siew-Veena Sahi and was founded in 2021. The company’s first product is a urine-based self-test for chlamydia and gonorrhea that delivers lab-quality results in less than 30 minutes. Testmate positions the device for use anywhere at any time and emphasizes diagnostic accuracy. The startup raised $6M in Seed funding to support development of the OTC STI self-test. Its team comprises experts in sexual health and diagnostics. Testmate Health is developing a rapid urine self-test that delivers at-home results in minutes for the four common sexually transmitted diseases and digitally connects users to healthcare professionals for consultation and prescription if needed. The company is finalizing its prototype, plans small-batch in-house manufacturing, and will enter pre-clinical studies at the Hopitaux Universitaires de Genève. Testmate recently closed a seed round (amount undisclosed) and received additional support from the Biopôle Start-up Fund. It will use the 90k Biopôle funds toward lab and office infrastructure, hiring commercial and regulatory consultants, and equipment to begin small-batch production of test kits. The team is simultaneously developing a go-to-market strategy in light of COVID-driven changes to the self-test landscape and aims to open a Series A at the beginning of 2023. Testmate Health is an award‑winning spin‑off of the University of Geneva building a rapid digital at‑home urine test for common STDs. The device is designed to detect chlamydia, gonorrhoea, trichomoniasis and Mycoplasma genitalium and to upload scanned results to a paired app to guide appropriate follow‑up. Its product aims to let customers skip clinic visits and avoid multi‑day waits by offering a simple, immediate self‑test. The start‑up closed an oversubscribed seed financing round totaling CHF1.6 million, with a first closing earlier in the spring and an extension to bring in additional investors. Proceeds will be used to accelerate product development and complete pre‑clinical studies of the device ahead of commercialisation. The financing also brings experienced advisers onto the governance team to support the next stages of development.